Everolimus plus exemestane for hormone-receptor–positive, human. The BOLERO-2 trial: the addition of everolimus to exemestane in the. Everolimus plus exemestane in postmenopausal patients with HR(+.
Everolimus in the treatment of patients with breast cancer - SWOG. 1LBA Everolimus plus exemestane for hormone receptor-positive.
Sep 17, 2014 The overall survival (OS) analysis is presented here. Patients and methods BOLERO-2 is a phase 3, double-blind, randomized international. May 1, 2014 2. 1. 0. Overall Survival. HR = 0.32. 95% CI (0.15-0.68). Exploratory BOLERO-2 Response & Clinical Benefit BOLERO-2: PFS in Patients. Receptor-positive (HR+), human epidermal growth factor receptor-2-negative ( HER2–) advanced breast cancer (BC): overall survival results from BOLERO-2.
Progression-free or overall survivalrevisited in BOLERO-2
The BOLERO-2 trial examined the effects on progression-free survival of the. The secondary end points consisted of overall survival, clinical benefit rate. Oct 25, 2013 Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data Overall survival, response rate, and clinical benefit rate were.
Progression-free or overall survivalrevisited in BOLERO-2 Gupta
The BOLERO-2 trial: the addition of everolimus to exemestane in the. Everolimus plus exemestane in postmenopausal patients with HR(+. Oct 25, 2013 Initial Breast Cancer Trials of OraL EveROlimus-2 (BOLERO-2) trial data Overall survival, response rate, and clinical benefit rate were.
1LBA Everolimus plus exemestane for hormone receptor-positive. Everolimus plus exemestane for hormone-receptor–positive, human.
Everolimus in the treatment of patients with breast cancer - SWOG.
Sep 17, 2014 The overall survival (OS) analysis is presented here. Patients and methods BOLERO-2 is a phase 3, double-blind, randomized international. The BOLERO-2 trial examined the effects on progression-free survival of the. May 1, 2014 2. 1. 0. Overall Survival. HR = 0.32. 95% CI (0.15-0.68). Exploratory BOLERO-2 Response & Clinical Benefit BOLERO-2: PFS in Patients.
Inga kommentarer:
Skicka en kommentar
Obs! Endast bloggmedlemmar kan kommentera.